We are live on ! Find out more
NC

Nexthera Capital Portfolio holdings

AUM $120M
1-Year Est. Return 10.01%
This Fund
S&P 500
This Quarter Est. Return
-20.14%
1 Year Est. Return
+10.01%
3 Year Est. Return
+160.68%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$243M
AUM Growth
-$279M
Cap. Flow
-$206M
Cap. Flow %
-85.09%
Top 10 Hldgs %
82.71%
Holding
61
New
5
Increased
9
Reduced
8
Closed
38

Top Buys

Rank Stock Value
1
NVS icon
Novartis
NVS
+$27.5M
2
HRTX icon
Heron Therapeutics
HRTX
+$20.1M
3
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$7.77M
4
INSM icon
Insmed
INSM
+$5.98M
5
BOLD
Audentes Therapeutics, Inc
BOLD
+$5.75M

Top Sells

Rank Stock Value
1
AGN
Allergan plc
AGN
+$30.2M
2
VTRS icon
Viatris
VTRS
+$25.5M
3
EXEL icon
Exelixis
EXEL
+$25.4M
4
DOVA
Dova Pharmaceuticals, Inc. Common Stock
DOVA
+$21.5M
5
TVRD
Tvardi Therapeutics
TVRD
+$17.7M

Sector Composition

Rank Sector Weight
1 Healthcare 57.29%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ACAD icon
26
Acadia Pharmaceuticals
ACAD
$4.51B
– –
-43,980
Closed -$913K
ADAP
27
DELISTED
Adaptimmune Therapeutics
ADAP
– –
-74,132
Closed -$1M
AZN icon
28
AstraZeneca
AZN
$269B
– –
-96,640
Closed -$7.65M
CARM
29
DELISTED
Carisma Therapeutics
CARM
– –
-58,850
Closed -$2.53M
CLSD
30
DELISTED
Clearside Biomedical
CLSD
– –
-12,067
Closed -$1.11M
DNTH icon
31
Dianthus Therapeutics
DNTH
$5.69B
– –
-9,375
Closed -$1.8M
KYNB
32
Kyntra Bio
KYNB
$27.4M
– –
-2,017
Closed -$3.06M
INSM icon
33
PUT
Insmed
INSM
$22.4B
– –
-250,000
Closed -$5.05M
IOVA icon
34
Iovance Biotherapeutics
IOVA
$2.04B
– –
-296,500
Closed -$3.34M
KURA icon
35
Kura Oncology
KURA
$793M
– –
-311,536
Closed -$5.45M
LLY icon
36
PUT
Eli Lilly
LLY
$1.08T
– –
-50,000
Closed -$5.37M
MDGL icon
37
Madrigal Pharmaceuticals
MDGL
$12.6B
– –
-4,000
Closed -$857K
NKTR icon
38
Nektar Therapeutics
NKTR
$2.39B
– –
-8,533
Closed -$7.8M
PFE icon
39
PUT
Pfizer
PFE
$143B
– –
-126,480
Closed -$5.29M
PRQR icon
40
ProQR Therapeutics
PRQR
$244M
– –
-52,875
Closed -$1.02M
SVRA icon
41
Savara
SVRA
$1.08B
– –
-97,600
Closed -$1.09M
TGTX icon
42
TG Therapeutics
TGTX
$8.19B
– –
-445,000
Closed -$2.49M
TXMD icon
43
TherapeuticsMD
TXMD
$23.8M
– –
-26,142
Closed -$8.57M
VKTX icon
44
Viking Therapeutics
VKTX
$3.88B
– –
-327,730
Closed -$5.71M
VTRS icon
45
Viatris
VTRS
$20.8B
– –
-695,788
Closed -$25.5M
TVRD
46
Tvardi Therapeutics
TVRD
$20.1M
– –
-20,481
Closed -$17.7M
MTEM
47
DELISTED
Molecular Templates, Inc.
MTEM
– –
-7,040
Closed -$569K
ACOR
48
DELISTED
Acorda Therapeutics
ACOR
– –
-417
Closed -$983K
NEOS
49
DELISTED
Neos Therapeutics, Inc
NEOS
– –
-311,502
Closed -$1.51M
AKRX
50
DELISTED
Akorn Inc
AKRX
– –
-35,000
Closed -$454K
1
2
3

Similar funds

KAM
Kavi Asset Management New York $121M AUM 7.54% 1-Year Est. Return
VCP
Vernier Capital Partners New York $132M AUM 20.75% 1-Year Est. Return
PFC
Personal Financial Consultants Lafayette, California $133M AUM 5.06% 1-Year Est. Return
FCA
Florence Capital Advisors New York $105M AUM
TA
TMD & Associates Scottsdale, Arizona $146M AUM 1.29% 1-Year Est. Return
EBIM
Eagle Boston Investment Management Boston, Massachusetts $87.3M AUM 4.18% 1-Year Est. Return
BCM
BBT Capital Management Fort Worth, Texas $85.5M AUM 11.09% 1-Year Est. Return
ACP
ArcLight Capital Partners Boston, Massachusetts $83.2M AUM 32.11% 1-Year Est. Return

Nexthera Capital's Q4 2018 Portfolio in Review

As of Q4 2018, Nexthera Capital held 61 positions worth $243M, down 54% from $522M the previous quarter. Its ten largest holdings account for 83% of the portfolio.

Nexthera Capital withdrew a net $206M in Q4 2018, closing 38 positions and reducing 8 holdings. Its most notable exit was Allergan plc, an estimated $30.2M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 57% of assets, down from 65% a quarter earlier.

Against the trend, Nexthera Capital opened a new position in Novartis worth $27.1M.

  • Nexthera Capital's largest Q4 2018 buy was Novartis: 352,787 shares worth $27.1M.
  • Nexthera Capital added most to Heron Therapeutics in Q4 2018, an estimated $20.1M increase.
  • Nexthera Capital's biggest Q4 2018 reduction was Exelixis, cutting an estimated $25.4M.
  • Nexthera Capital fully exited Allergan plc in Q4 2018, selling an estimated $30.2M.
  • Nexthera Capital's ten largest holdings make up 83% of its $243M portfolio in Q4 2018.
  • Nexthera Capital opened 5 new positions and closed 38 in Q4 2018.
  • Nexthera Capital's portfolio value fell 54% quarter-over-quarter to $243M.

Based on Nexthera Capital's 13F filing for Q4 2018, filed 14 Feb 2019.